-
Is it possible to bottle up all the health benefits of exercise into a pill?
22 Oct 2021 20:35 GMT
… macular degeneration, or AMD, the leading cause of blindness in the developed … as "exercise in a pill": delivering the molecular … .
Exercise 'in a pill'
At the molecular level … the treatment of others.
Of course, the creation of a drug …
-
Prozac Pegged As 1st Treatment For Leading Cause Of Blindness
21 Oct 2021 19:57 GMT
… macular degeneration is to run a
prospective clinical trial … drugs for many conditions, speeding new treatments to
patients.
“Traditional approaches to drug
development … an existing FDA-approved drug using big … medicines sitting on
pharmacy shelves.”
Findings …
-
1st Treatment for a Leading Cause of Blindness
21 Oct 2021 17:55 GMT
… macular degeneration is to run a prospective clinical trial … drugs for many conditions, speeding new treatments to patients.
“Traditional approaches to drug development … an existing FDA-approved drug using … medicines sitting on pharmacy shelves.”
Findings …
-
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
19 Oct 2021 12:34 GMT
… medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), … developing novel therapeutic compounds to treat genetically defined age-related macular degeneration … in a Phase 2a trial in dry AMD patients …
-
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct 2021 12:16 GMT
… FDA removed the clinical hold on its experimental cancer drug … wet age-related macular degeneration by the PDUFA … commercialization of pharmaceutical products to treat dermatological conditions. … NanoViricides COVID-19 Treatment Candidate Found Effective …
-
Regenxbio presents positive data from phase II ALTITUDE trial of RGX─314 to treat diabetic retinopathy using suprachoroidal delivery at ASRS meeting
12 Oct 2021 09:43 GMT
… in clinical development for the treatment of wet age-related macular degeneration and DR … providing additional updates on this trial next year."
"DR … treatment emergent adverse events in the study eye were not considered drug …
-
Worldwide Glaucoma Therapeutics Industry to 2026 - Featuring Novartis, Pfizer and SIFI Among Others
23 Oct 2021 02:17 GMT
… refers to various treatment alternatives for primary … such as age-related macular degeneration (AMD), cataract and … growth. Additionally, the development of innovative combination dugs … factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and …
-
The novel ocular drug delivery devices market is projected to grow at a CAGR of 15%, till 2030, claims Roots Analysis
13 Oct 2021 13:30 GMT
… drug delivery devices designed to treat … novel ocular drug delivery device developers?
Which … macular degeneration
Retinal diseases
Neovascular age-related macular degeneration …
EyePoint Pharmaceuticals
Genentech
Glaukos
Neurotech Pharmaceuticals
Ocular …
-
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
13 Oct 2021 06:22 GMT
… holds promise for treatment of wet AMD (Age-related Macular Degeneration) and RVO … a Phase 2, randomized, multicenter trial and is the first study … developed for additional vascular retinal disorders including for wet Age-related Macular Degeneration …
-
The novel ocular drug delivery devices market is projected to grow at a CAGR of 15%, till 2030, claims Roots Analysis
12 Oct 2021 12:45 GMT
… The delivery of drugs in ocular regions … challenging; several pharmaceutical companies are actively … novel ocular drug delivery device developers?
Which … -related macular degeneration
Retinal diseases
Neovascular age-related macular degeneration
…
About
© 1995-2021